Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site

MT Newswires Live

Apr 21

Recce Pharmaceuticals (ASX:RCE) said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.

The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.

The firm's shares rose 2% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2629059007"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629059007\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629059007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629059007","market":"sh","top_or_hot":-1,"title":"Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RECEF\">Recce Pharmaceuticals</a> (ASX:RCE) said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.</p><p>The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.</p><p>The firm's shares rose 2% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-21 10:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RECEF\">Recce Pharmaceuticals</a> (ASX:RCE) said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.</p><p>The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.</p><p>The firm's shares rose 2% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCE.AU","symbol_name":"RECCE PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629059007","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629059007","pubTimestamp":1776738396,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Recce Pharmaceuticals  said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.The firm's shares rose 2% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCE.AU":"RECCE PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Recce Pharmaceuticals表示印尼监管机构完成对三期临床试验场所的例行监管检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCE.AU":1},"content_text":"Recce Pharmaceuticals (ASX:RCE) said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.The firm's shares rose 2% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}